𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial

✍ Scribed by Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg; Robert E. Allen; Stanley P. L. Leong; Eric J. Small

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
75 KB
Volume
86
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma.

METHODS.

Nineteen patients were treated with intravenous cisplatin and dacarbazine (DTIC), oral tamoxifen, and subcutaneous IL-2 and interferon-␣-2b (IFN).

Eligibility requirements included bidimensionally measurable metastatic melanoma, a Karnofsky performance score of 60 or higher, absence of significant cardiac or pulmonary dysfunction, no prior DTIC or cisplatin chemotherapy, and no evidence of central nervous system involvement. Patients were given a minimum of 2 6-week cycles. Treatment was continued in the absence of progressive disease, and patients were monitored for response at two-cycle intervals.

πŸ“œ SIMILAR VOLUMES

Results of a phase II trial of combined
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura
✍ SΓ©bastien Kasseyet; Philippe Astoul; Christian Boutin πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 283 KB πŸ‘ 1 views

## BACKGROUND. Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment. The authors conducted a Phase II trial in which two drugs (etoposide and 5-fluorouracil) were added to the Cancer and Leukemia Group B cisplatin-mitomycin regimen in an effort t

Granulocyte-macrophage–colony stimulatin
Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f